semaglutide 7.2 mg clinical trial Efficacy and safety of once-weekly 2·0 versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B Semaglutide Shines as Weight Loss

Researchers examine this compound as a tri-agonist that interacts with SP-1, GIP, and glucagon receptors at the molecular level

When you maintain a calorie deficit , your body begins drawing on stored energy from multiple fat stores

As mentioned earlier, Noom Med connects you to a licensed clinician who can assess your health history and determine if prescription GLP-1s or weight-loss medications are right for you

4.6.2 Retinal disease Diabetic retinopathy (DR) is the most prevalent microvascular complication of diabetes and the leading cause of preventable blindness among working-age individuals (81)

Response-Based Approach: Treatment duration is individualized based on objective measurements including body composition analysis (DEXA scan, bioimpedance), waist circumference, metabolic markers, and subjective response